Clinical trial
Phase 2/3 Trial of Autologous Hybrid TREG/Th2 (RAPA-501) T Stem Cell Therapy for Amyotrophic Lateral Sclerosis
NCT04220190 is registered in ClinicalTrials.gov with Rapa Therapeutics LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2/3 Trial of Autologous Hybrid TREG/Th2 (RAPA-501) T Stem Cell Therapy for Amyotrophic Lateral Sclerosis
- Lead sponsor
- Rapa Therapeutics LLC
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- January 2, 2025
- Completion date
- July 1, 2028
- Enrollment
- 41 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.